Bank of New York Mellon Corp Takes Position in Medpace Holdings, Inc. $MEDP

Key Points

• Bank of New York Mellon acquired 146,588 Medpace shares worth approximately $77.6 million, representing a 0.53% stake; institutional investors collectively own about 78% of the company.
• Medpace exceeded quarterly expectations, reporting $4.25 EPS versus $3.98 expected and $707.33 million in revenue, up 17.2% year over year. Fiscal 2026 EPS guidance is $17.25–$17.95.
• Investor sentiment is mixed: analysts maintain a consensus “Hold” rating with a $584.18 average price target, while insiders sold substantial shares recently, including CFO and director transactions.

Bank of New York Mellon Corp bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 146,588 shares of the company's stock, valued at approximately $77,632,000. Bank of New York Mellon Corp owned 0.53% of Medpace as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MEDP. Focus Partners Advisor Solutions LLC acquired a new stake in Medpace during the second quarter valued at approximately $1,685,000. State of Wyoming acquired a new position in shares of Medpace in the 2nd quarter worth approximately $88,000. GSA Capital Partners LLP bought a new position in shares of Medpace during the 2nd quarter worth approximately $208,000. MGO One Seven LLC boosted its stake in Medpace by 7.1% in the 2nd quarter. MGO One Seven LLC now owns 968 shares of the company's stock valued at $513,000 after buying an additional 64 shares in the last quarter. Finally, Associated Banc Corp acquired a new stake in Medpace in the 2nd quarter valued at $204,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Down 1.0%

Shares of NASDAQ MEDP opened at $614.06 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $373.00 and a 12-month high of $677.90. The firm's 50-day simple moving average is $556.26 and its 200 day simple moving average is $492.77. The company has a market cap of $17.14 billion, a price-to-earnings ratio of 35.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts' expectations of $689.51 million. During the same quarter last year, the company posted $3.10 EPS. The company's quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Kevin M. Brady sold 3,400 shares of the business's stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total value of $2,125,816.00. Following the completion of the transaction, the chief financial officer owned 12,830 shares in the company, valued at $8,021,829.20. The trade was a 20.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the transaction, the director owned 12,275 shares of the company's stock, valued at $7,430,916.75. This trade represents a 8.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 141,639 shares of company stock valued at $83,824,038 over the last quarter. Company insiders own 20.50% of the company's stock.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of analyst reports. Robert W. Baird lifted their price objective on Medpace from $547.00 to $624.00 and gave the company a "neutral" rating in a report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and upped their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. BMO Capital Markets increased their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research report on Friday, July 24th. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a "hold" rating in a report on Friday, July 24th. Finally, Mizuho boosted their price target on shares of Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Medpace presently has an average rating of "Hold" and an average price target of $584.18.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure.
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.”
• Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source